Acomplia approved for weight-loss but not anti-smoking

02/18/2006 | Philadelphia Inquirer, The

In a setback for Sanofi-Aventis, the U.S. FDA gave Acomplia the go-ahead for use as a weight-loss drug but did not approve its use as a smoking-cessation treatment. The FDA did not give a reason for the decision and did not outline conditions for Sanofi-Aventis to gain approval. The company says it will work with the federal agency.

View Full Article in:

Philadelphia Inquirer, The

Published in Brief:

SmartBrief Job Listings for Health Care